TiH presents findings of cost-effectiveness study at the 2019 ACR/ARP Annual Meeting
TiH researcher Celine van de Laar was invited to present the findings of a new study comparing the cost-effectiveness of various combinations of urate lowering therapy and anti-inflammatory treatment for patients with gout at the 2019 ACR/ARP Annual Meeting. Costs and quality-adjusted life years associated with each treatment strategy were compared using patient-level simulation modelling, with data from our recently completed ATTACG trial as the primary data source for model input. The results of the study showed that both allopurinol and febuxostat were cost-effective treatment options, while anakinra was not cost-effective.
The published abstract of the presentation can be found here.